| Michael J Leddy Iii, MD | |
|
3351 Masonic Dr, Alexandria, LA 71301-3842 | |
| (318) 473-9556 | |
| (318) 441-8339 |
| Full Name | Michael J Leddy Iii |
|---|---|
| Gender | Male |
| Speciality | Sports Medicine |
| Experience | 27 Years |
| Location | 3351 Masonic Dr, Alexandria, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821052028 | NPI | - | NPPES |
| 4K904F735 | Other | LA | LA MEDICARE NUMBER |
| 1484831 | Medicaid | LA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Louisiana Surgical Hospital | Alexandria, LA | Hospital |
| Christus St Frances Cabrini Hospital | Alexandria, LA | Hospital |
| Rapides Regional Medical Center | Alexandria, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid State Orthopaedic And Sports Medicine Center Llc | 6204892540 | 26 |
News Archive
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Patients with systolic hypertension who were treated with the diuretic chlorthalidone for 4.5 years as part of a clinical trial had a significantly lower rate of death and a gain in life expectancy free from cardiovascular death about 20 years later compared to patients who received placebo, according to a study in the December 21 issue of JAMA.
Estrogen is the quintessentially female hormone. It is surprising, then, that a Medical University of South Carolina study found that a type of estrogen, estradiol, was more abundant in older men with scleroderma than in postmenopausal women with the disease.
One of every eight women in the United States will develop breast cancer. Though the incidence of breast cancer began decreasing in 2000, it is still the second-leading cause of cancer death in women.
› Verified 9 days ago
| Entity Name | Mid State Orthopaedic & Sports Medicine Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104890052 PECOS PAC ID: 6204892540 Enrollment ID: O20041208000292 |
News Archive
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Patients with systolic hypertension who were treated with the diuretic chlorthalidone for 4.5 years as part of a clinical trial had a significantly lower rate of death and a gain in life expectancy free from cardiovascular death about 20 years later compared to patients who received placebo, according to a study in the December 21 issue of JAMA.
Estrogen is the quintessentially female hormone. It is surprising, then, that a Medical University of South Carolina study found that a type of estrogen, estradiol, was more abundant in older men with scleroderma than in postmenopausal women with the disease.
One of every eight women in the United States will develop breast cancer. Though the incidence of breast cancer began decreasing in 2000, it is still the second-leading cause of cancer death in women.
› Verified 9 days ago
| Entity Name | Lsuhn Billing Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992975775 PECOS PAC ID: 0446337802 Enrollment ID: O20080409000372 |
News Archive
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Patients with systolic hypertension who were treated with the diuretic chlorthalidone for 4.5 years as part of a clinical trial had a significantly lower rate of death and a gain in life expectancy free from cardiovascular death about 20 years later compared to patients who received placebo, according to a study in the December 21 issue of JAMA.
Estrogen is the quintessentially female hormone. It is surprising, then, that a Medical University of South Carolina study found that a type of estrogen, estradiol, was more abundant in older men with scleroderma than in postmenopausal women with the disease.
One of every eight women in the United States will develop breast cancer. Though the incidence of breast cancer began decreasing in 2000, it is still the second-leading cause of cancer death in women.
› Verified 9 days ago
| Entity Name | University Hospital & Clinics, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639518087 PECOS PAC ID: 7113161977 Enrollment ID: O20130917000335 |
News Archive
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Patients with systolic hypertension who were treated with the diuretic chlorthalidone for 4.5 years as part of a clinical trial had a significantly lower rate of death and a gain in life expectancy free from cardiovascular death about 20 years later compared to patients who received placebo, according to a study in the December 21 issue of JAMA.
Estrogen is the quintessentially female hormone. It is surprising, then, that a Medical University of South Carolina study found that a type of estrogen, estradiol, was more abundant in older men with scleroderma than in postmenopausal women with the disease.
One of every eight women in the United States will develop breast cancer. Though the incidence of breast cancer began decreasing in 2000, it is still the second-leading cause of cancer death in women.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael J Leddy Iii, MD 3444 Masonic Dr, Alexandria, LA 71301-3615 Ph: (318) 473-9556 | Michael J Leddy Iii, MD 3351 Masonic Dr, Alexandria, LA 71301-3842 Ph: (318) 473-9556 |
News Archive
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Patients with systolic hypertension who were treated with the diuretic chlorthalidone for 4.5 years as part of a clinical trial had a significantly lower rate of death and a gain in life expectancy free from cardiovascular death about 20 years later compared to patients who received placebo, according to a study in the December 21 issue of JAMA.
Estrogen is the quintessentially female hormone. It is surprising, then, that a Medical University of South Carolina study found that a type of estrogen, estradiol, was more abundant in older men with scleroderma than in postmenopausal women with the disease.
One of every eight women in the United States will develop breast cancer. Though the incidence of breast cancer began decreasing in 2000, it is still the second-leading cause of cancer death in women.
› Verified 9 days ago
Dr. Kevin D Keith, D.O. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 201 4th St Ste 1ds, Alexandria, LA 71301 Phone: 318-443-7622 | |
Dr. Douglas L Gamburg, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 224 Pecan Park Ave, Alexandria, LA 71303 Phone: 318-443-9191 Fax: 318-443-9190 | |
Daniel R Oas, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: Mid State Orthoapedic And Sports Medicine Center, Llc, 3444 Masonic Drive, Alexandria, LA 71301 Phone: 318-473-9556 Fax: 318-441-8339 | |
Mr. Jeffrey L Garrison, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3444 Masonic Drive, Alexandria, LA 71301 Phone: 318-473-9556 Fax: 318-441-8339 | |
Louis Donovan Perdue, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 3351 Masonic Drive, Alexandria, LA 71301 Phone: 318-473-9556 Fax: 318-441-8339 | |
Mr. Timmothy R Randell, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3444 Masonic Drive, Alexandria, LA 71301 Phone: 318-473-9556 Fax: 318-441-8339 | |
Brad Chauvin, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 4th St, Suite 1d, Alexandria, LA 71301 Phone: 318-443-7622 Fax: 318-443-7629 |